Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Management of Bipolar Affective Disorders Manic Episode • Persistently elevated,expansive or irritable mood for at least a week • Presence of at least 3 typical symptoms: decreased need for sleep, flight of ideas,grandiosity, uncharacteristic risk taking, distractibility, agitation, increase in pleasurable activities • Marked impairment of functioning, necessity for hospitalisation, or psychotic features Hypomania • Impairment is less severe • Psychotic features are absent • Social and occupational functioning are not significantly impaired • Hospitalisation is usually not required Mixed Episode • Depressive symptoms occur in the context of manic thinking • Depressive and manic symptoms alternate from day to day or even hour to hour • Unpleasant agitation is common Bipolar Affective Disorder • Bipolar I Disorder A recurrent mood disorder featuring one or more manic or mixed episodes, or both manic and mixed episodes and at least one major depressive episode • Bipolar II Disorder Characterised by one or more episodes of major depression and at least one hypomanic episode • Cyclothymia Persistent instability of mood (> 2 years duration) featuring numerous periods of mild depression and elation, none of which meet the criteria for depression or mania Cycle Frequency • Manic episodes last between 2 weeks and 5 months • Depressive episodes have a mean duration of 6 months • 10-20% of people with bipolar disorder experience rapid cycling, characterised by 4 or more episodes of depression or mania per year and only short euthymic episode in between • A rapid cycling pattern is often associated with a poor prognosis Epidemiology • Bipolar disorder (I +II) has a prevalence of 1.3% in the UK • Estimates suggest that approximately 0.5 million people over 15 in England and Wales are affected • Bipolar I disorder affects men and women equally, but bipolar II is commoner in women • Unlike schizophrenia, it is prevalent in higher social classes • In the USA, an average delay to diagnosis of 6 years is common Course of the Illness • Peak age of onset is 15-24 years • If onset occurs >60 years think of an organic cause • More than 90% of people who have a single manic episode will have a recurrence • 10-15% will have more than 10 episodes in their lifetime • Lifetime suicide risk is 15-19% • Co-morbid drug and alcohol misuse is common Aetiological Factors • Genetic – Mode of inheritance is complex, likely to involve several genes – Lifetime risk of developing bipolar disorder • First degree relatives • Monozygotic twins • Dizygotic twins 11% 79% 19% Birth Effects • Excess of spring and winter births and maternal fever Pathophysiology • Neurotransmitter Dysfunction – ? deficits in Na+K+ATPase and second messenger systems – ?serotonin system dysfunction Neuroendocrine Dysfunction – Grade II hypothyroidism is found in 25% of rapid cycling bipolar patients compared with 2-5% in depression Pathophysiology (cont) Brain Structural Changes Gross pathology associated with a poor prognosis – – – – smaller temporal lobes and caudate nuclei Patchy white matter lesions on MRI Pre-frontal-limbic subcortical abnormalities reduced blood flow in the pre-frontal cortex – hypofrontal pattern of glucose metabolism – frontal lobe dysfunction in BPD I Fundamentals of Patient Management • Diagnosis • Access to services and safety • Enhanced Care Delays to Diagnosis • Irritability or aggression may be misdiagnosed as personality disorder in the absence of mood elevation • Adolescent behavioural disturbance • Substance misuse • Exclude causes of 2o mania Access to Services and Safety • Involve a psychiatrist in assessment and management • Mania or psychotic depression are psychiatric emergencies • Hospital admission or intensive community management • The Mental Health Act is often required • Early Intervention Teams Assessment of Risk • Ideally involve an informant • • • • • Suicide Excessive spending Sexual promiscuity Driving Violence Enhanced Care • Establish and maintain a therapeutic alliance – Treatment adherence – Education Awareness of early signs of relapse – – – – recognise stressors manage sleep disturbance promote regular patterns of activity involve the family • Manage functional impairments – withdrawal from work (average 12 weeks) – discourage major decisions – consider needs of children and carers Treatment of different phases of bipolar disorder • Acute manic or mixed episode • Acute depressive episode • Long-term treatment • Pregnancy and the post-partum period Acute Manic/Mixed Episode • Use atypical antipsychotics + mood stabiliser • Benzodiazepines are useful short term to promote sleep • Additional medications should be tapered and stopped as symptoms improve Acute Depressive Episode • Risk of mania or rapid cycling with use of antidepressant • Ideally treat with mood stabiliser alone • SSRIs are less likely to promote manic switch • Discontinue the antidepressant when symptoms remit (e.g. 12 weeks) Treatment of bipolar depression • Aim to treat depression without causing switching or destabilising mood • Ideally use a mood stabiliser or a combination of 2 • Lamotrigine is an antidepressant mood stabiliser • Use antidepressants with caution – modern antidepressants (SSRI, SNRI) – short courses – long term treatment is only suitable for those who repeatedly relapse on withdrawal Mental Health Register • Regular (annual) physical health checks • Relevant blood tests • Need to establish between primary and secondary care respective responsibilities Longterm Treatment:Drugs • Mood stabilisers are drugs that prevent relapse to either pole of the illness • Some mood stabilisers are more effective against mania (lithium, olanzapine) or depression (lamotrigine) Lithium – response rate 70-80% – associated with reduced suicide rate compared with other mood stabilisers – associated with weight gain, polyuria, polydipsia – toxic side effects and potentially fatal in overdose – risk of irreversible renal and thyroid damage – rapid discontinuation is linked to marked affective instability and suicide risk Monitoring Lithium Therapy • Serum Lithium levels 3-6 monthly • U+E, Thyroid function and calcium every 6 months Anticonvulsants as mood stabilisers • Anticonvulsants as mood stabilisers – – – – – sodium valproate (Epilim, Depakote) carbamazepine (tegretol) lamotrigine (lamictal) gabapentin topiramate Monitoring of full blood count and liver function are required 6 monthly Potential for drug interactions Atypical Antipsychotics • Recently licensed for acute and maintenance treatment – Olanzapine – Quetiapine – Risperidone 6 monthly glucose monitoring required with atypical antipsychotics Combination therapies • • • • Combination of two mood stabilisers An antipsychotic and a mood stabiliser An antidepressant and a mood stabiliser Short term add-ons (hypnotics and antipsychotics) Non-pharmacological strategies • • • • • • Facilitate acceptance of the disorder Identify and manage psychosocial stressors Improve medication adherence Recognition of early signs of relapse Empower the individual Identify and modify maladaptive thinking patterns Does Cognitive Therapy improve Outcome in BPD? • CBT has been shown to – improve compliance with medication – reduce admissions / bed days for mania – improve social functioning Bipolar Disorder and Pregnancy • Compliance with treatment during pregnancy – maintenance of mental health – normal bonding – risk of teratogenesis – neonatal side effects Risk of congenital malformation • • • • Normal population Lithium exposed Valproate exposed Carbamazepine exposed 2-4% 4-12% 11% 6% Specific teratogenic associations • Lithium 0.05-0.1% risk of cardiovascular anomalies • Valproate and Carbamazepine 1-2 % risk of congenital abnormality including neural tube defect and foetal hydantoin syndrome Pregnancy and bipolar disorder Pregnancy should be planned Treatment options depend on patient history and preference – withdrawal of medication – change of medication – lowering dose (slow release formulations) Those exposed to teratogens in the first trimester should be offered high resolution ultrasound scan at 16-18 weeks gestation Maternal physiological changes result in variable serum levels of mood stabilisers especially lithium Postpartum • Toxic and withdrawal effects of mood stabilisers in neonates • All drugs enter breast milk. Breast feeding not advised for lithium takers • Increased risk of first admission postpartum • Increased risk of suicide (and infanticide) Evidence Based Guidelines for Treating Bipolar Disorder • www.bap.domainwarehouse.com/consensus /FinalBipolarGuidelines.pdf